Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer.

ABSTRACT:

Background

The SCOPE-1 study tested the role of adding cetuximab to conventional definitive chemoradiotherapy (dCRT), and demonstrated greater toxicity and worse survival outcomes. We present the long-term outcomes and patterns of recurrence.

Methods

SCOPE-1 was a phase II/III trial in which patients were randomised to cisplatin 60 mg m^-2 (day 1) and capecitabine 625 mg m^-2 bd (days 1-21) for four cycles +/- cetuximab 400 mg m^-2 day 1 then by 250 mg m^-2 weekly. Radiotherapy consisted of 50 Gy/25# given concurrently with cycles 3 and 4. Recruitment was between February 2008 and February 2012, when the IDMC recommended closure on the basis of futility.

Results

About 258 patients (dCRT=129; dCRT+cetuximab (dCRT+C)=129) were rec

SUBMITTER: Crosby T 

PROVIDER: S-EPMC5355926 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature